Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

High-Risk Human Papillomavirus Detection in Urine Samples From a Referral Population With Cervical Biopsy-Proven High-Grade Lesions.

Lorenzi AT, Fregnani JHT, Dockter J, Fitzgerald K, Strohecker E, Eaton B, Vibat CRT, Erlander MG, Scapulatempo-Neto C, Smith JS, Longatto-Filho A.

J Low Genit Tract Dis. 2018 Jan;22(1):17-20. doi: 10.1097/LGT.0000000000000352.

PMID:
29271852
2.

Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.

Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS.

Oncotarget. 2017 Oct 26;8(58):97769-97786. doi: 10.18632/oncotarget.22080. eCollection 2017 Nov 17.

3.

Urine test for EGFR analysis in patients with non-small cell lung cancer.

Franovic A, Raymond VM, Erlander MG, Reckamp KL.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1323-S1331. doi: 10.21037/jtd.2017.06.144. Review.

4.

Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.

Tchekmedyian N, Mudad R, Blanco FF, Raymond VM, Garst J, Erlander MG, Haura E, Berz D.

Lung Cancer. 2017 Jun;108:22-28. doi: 10.1016/j.lungcan.2017.02.010. Epub 2017 Feb 20.

PMID:
28625639
5.

Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.

Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R.

Clin Cancer Res. 2017 Aug 15;23(16):4716-4723. doi: 10.1158/1078-0432.CCR-17-0454. Epub 2017 Apr 18.

6.

Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population.

Cuzick J, Cadman L, Ahmad AS, Ho L, Terry G, Kleeman M, Lyons D, Austin J, Stoler MH, Vibat CRT, Dockter J, Robbins D, Billings PR, Erlander MG.

Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1053-1059. doi: 10.1158/1055-9965.EPI-16-0960. Epub 2017 Feb 21.

7.

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.

Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F.

Clin Cancer Res. 2017 Jul 15;23(14):3657-3666. doi: 10.1158/1078-0432.CCR-16-2592. Epub 2017 Jan 17.

8.

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.

Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S, Geis J, Berz D, Mann E, Matheny S, Rolfe L, Raponi M, Erlander MG, Gadgeel S.

J Thorac Oncol. 2016 Oct;11(10):1690-700. doi: 10.1016/j.jtho.2016.05.035. Epub 2016 Jul 25.

9.

Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.

Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, Pollak MN.

Breast Cancer Res Treat. 2016 May;157(1):101-8. doi: 10.1007/s10549-016-3806-z. Epub 2016 Apr 26.

PMID:
27116182
10.

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SH, Ali SM.

Cancer Discov. 2016 Jun;6(6):594-600. doi: 10.1158/2159-8290.CD-15-1192. Epub 2016 Apr 5.

11.

Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.

Sgroi DC, Chapman JA, Badovinac-Crnjevic T, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Goss PE, Pollak M.

Breast Cancer Res. 2016 Jan 4;18(1):1. doi: 10.1186/s13058-015-0660-6.

12.

Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer.

Senkomago V, Des Marais AC, Rahangdale L, Vibat CR, Erlander MG, Smith JS.

J Clin Virol. 2016 Jan;74:26-31. doi: 10.1016/j.jcv.2015.11.005. Epub 2015 Nov 6.

PMID:
26655264
13.

Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer.

Berz D, Raymond VM, Garst JH, Erlander MG.

Exp Hematol Oncol. 2016 Aug 8;5:24. doi: 10.1186/s40164-016-0052-3. eCollection 2015.

14.

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.

Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O.

Cancer Discov. 2015 Jan;5(1):64-71. doi: 10.1158/2159-8290.CD-14-0742. Epub 2014 Oct 16.

15.

Health economic analysis of Breast Cancer Index in patients with ER+, LN- breast cancer.

Gustavsen G, Schroeder B, Kennedy P, Pothier KC, Erlander MG, Schnabel CA, Ali H.

Am J Manag Care. 2014 Aug 1;20(8):e302-10.

16.

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.

Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L, Poole JC, Kurzrock R, Erlander MG.

Oncotarget. 2014 Jun 15;5(11):3607-10.

17.

Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer.

Bentley TG, Schroeder BE, Schnabel CA, Erlander MG, Hsiao WC, Ortendahl JD, Broder MS.

J Med Econ. 2014 Aug;17(8):527-37. doi: 10.3111/13696998.2014.909817. Epub 2014 May 14.

PMID:
24689556
18.

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M.

Lancet Oncol. 2013 Oct;14(11):1067-1076. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

19.

A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors.

Kerr SE, Schnabel CA, Sullivan PS, Zhang Y, Huang VJ, Erlander MG, Brachtel EF, Dry SM.

Mod Pathol. 2014 Jan;27(1):44-54. doi: 10.1038/modpathol.2013.105. Epub 2013 Jul 12.

20.

Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE.

J Natl Cancer Inst. 2013 Jul 17;105(14):1036-42. doi: 10.1093/jnci/djt146. Epub 2013 Jun 28.

21.

Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.

Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, Stål O, Brufsky AM, Sgroi D, Erlander MG.

Clin Cancer Res. 2013 Aug 1;19(15):4196-205. doi: 10.1158/1078-0432.CCR-13-0804. Epub 2013 Jun 11.

22.

Development and validation of a 32-gene prognostic index for prostate cancer progression.

Wu CL, Schroeder BE, Ma XJ, Cutie CJ, Wu S, Salunga R, Zhang Y, Kattan MW, Schnabel CA, Erlander MG, McDougal WS.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6121-6. doi: 10.1073/pnas.1215870110. Epub 2013 Mar 26.

23.

HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.

Habel LA, Sakoda LC, Achacoso N, Ma XJ, Erlander MG, Sgroi DC, Fehrenbacher L, Greenberg D, Quesenberry CP Jr.

Breast Cancer Res. 2013 Mar 14;15(2):R24. doi: 10.1186/bcr3402.

24.

Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors.

Schnabel CA, Erlander MG.

Expert Opin Med Diagn. 2012 Sep;6(5):407-19. doi: 10.1517/17530059.2012.704363. Epub 2012 Jul 10.

PMID:
23480806
25.

Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors.

Weiss LM, Chu P, Schroeder BE, Singh V, Zhang Y, Erlander MG, Schnabel CA.

J Mol Diagn. 2013 Mar;15(2):263-9. doi: 10.1016/j.jmoldx.2012.10.001. Epub 2012 Dec 31.

PMID:
23287002
26.

Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier.

Kerr SE, Schnabel CA, Sullivan PS, Zhang Y, Singh V, Carey B, Erlander MG, Highsmith WE, Dry SM, Brachtel EF.

Clin Cancer Res. 2012 Jul 15;18(14):3952-60. doi: 10.1158/1078-0432.CCR-12-0920. Epub 2012 May 30.

27.

Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy.

Mathieu MC, Mazouni C, Kesty NC, Zhang Y, Scott V, Passeron J, Arnedos M, Schnabel CA, Delaloge S, Erlander MG, André F.

Ann Oncol. 2012 Aug;23(8):2046-52. doi: 10.1093/annonc/mdr550. Epub 2011 Nov 22.

PMID:
22112967
28.

A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.

Hainsworth JD, Schnabel CA, Erlander MG, Haines DW 3rd, Greco FA.

Clin Colorectal Cancer. 2012 Jun;11(2):112-8. doi: 10.1016/j.clcc.2011.08.001. Epub 2011 Oct 14.

PMID:
22000811
29.

Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.

Jankowitz RC, Cooper K, Erlander MG, Ma XJ, Kesty NC, Li H, Chivukula M, Brufsky A.

Breast Cancer Res. 2011 Oct 14;13(5):R98. doi: 10.1186/bcr3038.

30.

Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification.

Erlander MG, Ma XJ, Kesty NC, Bao L, Salunga R, Schnabel CA.

J Mol Diagn. 2011 Sep;13(5):493-503. doi: 10.1016/j.jmoldx.2011.04.004. Epub 2011 Jun 25.

31.

Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.

Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, Sgroi DC, Holmlund B, Skoog L, Fornander T, Nordenskjöld B, Stål O.

Br J Cancer. 2011 May 24;104(11):1762-9. doi: 10.1038/bjc.2011.145. Epub 2011 May 10.

32.

Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction.

Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ, Hainsworth JD.

Oncologist. 2010;15(5):500-6. doi: 10.1634/theoncologist.2009-0328. Epub 2010 Apr 28.

33.

Molecular classification of cancers of unknown primary site.

Greco FA, Erlander MG.

Mol Diagn Ther. 2009 Dec 1;13(6):367-73. doi: 10.2165/11530360-000000000-00000. Review.

PMID:
19925034
34.

Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.

McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman J.

Cancer Res. 2009 May 1;69(9):3937-46. doi: 10.1158/0008-5472.CAN-08-4327. Epub 2009 Apr 14.

35.

Molecular classification of unknown primary cancer.

Bender RA, Erlander MG.

Semin Oncol. 2009 Feb;36(1):38-43. doi: 10.1053/j.seminoncol.2008.10.002. Review.

PMID:
19179186
36.

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.

Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN.

Clin Cancer Res. 2008 Sep 15;14(18):5864-8. doi: 10.1158/1078-0432.CCR-08-0619.

37.

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.

McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.

Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. Epub 2007 Dec 6.

38.

The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.

Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG.

J Clin Oncol. 2006 Oct 1;24(28):4611-9.

PMID:
17008703
39.

RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.

Sgroi DC, Haber DA, Ryan PD, Ma XJ, Erlander MG.

Cancer Cell. 2004 Nov;6(5):445. No abstract available.

40.

Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli.

Peterson KS, Huang JF, Zhu J, D'Agati V, Liu X, Miller N, Erlander MG, Jackson MR, Winchester RJ.

J Clin Invest. 2004 Jun;113(12):1722-33.

41.

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.

Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC.

Cancer Cell. 2004 Jun;5(6):607-16.

42.

Laser capture microdissection and advanced molecular analysis of human breast cancer.

Fuller AP, Palmer-Toy D, Erlander MG, Sgroi DC.

J Mammary Gland Biol Neoplasia. 2003 Jul;8(3):335-45. Review.

PMID:
14973377
43.

Gene expression profiles of human breast cancer progression.

Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9. Epub 2003 Apr 24.

44.

Global gene expression analysis of single cells.

Kamme F, Erlander MG.

Curr Opin Drug Discov Devel. 2003 Mar;6(2):231-6. Review.

PMID:
12669459
45.

Laser capture microdissection and its applications in genomics and proteomics.

Wittliff JL, Erlander MG.

Methods Enzymol. 2002;356:12-25. No abstract available.

PMID:
12418184
46.

Nuclei and subnuclei gene expression profiling in mammalian brain.

Bonaventure P, Guo H, Tian B, Liu X, Bittner A, Roland B, Salunga R, Ma XJ, Kamme F, Meurers B, Bakker M, Jurzak M, Leysen JE, Erlander MG.

Brain Res. 2002 Jul 5;943(1):38-47.

PMID:
12088837
47.

Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles.

Lovenberg TW, Pyati J, Chang H, Wilson SJ, Erlander MG.

J Pharmacol Exp Ther. 2000 Jun;293(3):771-8.

48.

TOGA: an automated parsing technology for analyzing expression of nearly all genes.

Sutcliffe JG, Foye PE, Erlander MG, Hilbush BS, Bodzin LJ, Durham JT, Hasel KW.

Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):1976-81.

49.

Anatomical distribution of prolactin-releasing peptide and its receptor suggests additional functions in the central nervous system and periphery.

Roland BL, Sutton SW, Wilson SJ, Luo L, Pyati J, Huvar R, Erlander MG, Lovenberg TW.

Endocrinology. 1999 Dec;140(12):5736-45.

PMID:
10579339
50.

Immune-associated nucleotide-1 (IAN-1) is a thymic selection marker and defines a novel gene family conserved in plants.

Poirier GM, Anderson G, Huvar A, Wagaman PC, Shuttleworth J, Jenkinson E, Jackson MR, Peterson PA, Erlander MG.

J Immunol. 1999 Nov 1;163(9):4960-9.

Supplemental Content

Loading ...
Support Center